TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29752413

Group type: EXPERIMENTAL
Intervention: Everolimus with reduced-exposure CNI
Number of subjects: 2037

Group type: COMPARATOR
Intervention: Mycophenolic acid (MPA) with standard-exposure CNI
Number of subjects: 2037
Study: 27345496

Group type: EXPERIMENTAL
Intervention: Docetaxel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 25210200

Group type: EXPERIMENTAL
Intervention: RFA followed by [(131)I] metuximab (n = 62)
Number of subjects: 127

Group type: COMPARATOR
Intervention: RFA alone (n = 65)
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: RFA followed by [(131)I] metuximab in CD147-positive subpopulation
Number of subjects: 127
Study: 23132292

Group type: EXPERIMENTAL
Intervention: Pixon-processed half-count scans
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Half-count scans
Number of subjects: 150

Group type: COMPARATOR
Intervention: Full-count scans
Number of subjects: 150
Study: 19344226

Group type: EXPERIMENTAL
Intervention: Higher FAI (Free Androgen Index)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Lower SHBG (Sex Hormone-Binding Globulin)
Number of subjects: 200

Group type: COMPARATOR
Intervention: CVD cases
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: BMI adjustment
Number of subjects: 200
Study: 18595488

Group type: EXPERIMENTAL
Intervention: Lichtenstein hernia repair
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (healthy males)
Number of subjects: 40
Study: 15601638

Group type: EXPERIMENTAL
Intervention: Methotrexate and 5-fluorouracil (MF)
Number of subjects: 3863

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide with Methotrexate and 5-fluorouracil (CMF)
Number of subjects: 3863

Group type: COMPARATOR
Intervention: Cyclophosphamide and Doxorubicin (AC)
Number of subjects: 3863

Group type: COMPARATOR
Intervention: CMF or AC (combined)
Number of subjects: 3863
Study: 11176767

Group type: EXPERIMENTAL
Intervention: Methylphenidate hydrochloride (Ritalin)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Pemoline (Cylert)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Psychostimulants (Methylphenidate and Pemoline combined)
Number of subjects: 144
Study: 9492508

Group type: EXPERIMENTAL
Intervention: Low flow anesthesia (group L): oxygen 0.5 l.min‐1, nitrous oxide 0.5 l.min‐1, isoflurane
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard flow anesthesia (group H): oxygen 2 l.min‐1, nitrous oxide 4 l.min‐1, isoflurane
Number of subjects: 30
Study: 8056738

Group type: EXPERIMENTAL
Intervention: Naltrexone administration
Number of subjects: 1

Group type: COMPARATOR
Intervention: Control sessions
Number of subjects: 1
Study: 3178489

Group type: EXPERIMENTAL
Intervention: hGH (group 2)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: hGH (group 3)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo (group 1)
Number of subjects: 19
Study: 4204790

Group type: EXPERIMENTAL
Intervention: 3200 IU of vitamin E daily
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Regular daily dose of vitamin E (400 to 2400 IU)
Number of subjects: 55
Study: 31264773

Group type: EXPERIMENTAL
Intervention: Labor induction at 39 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Composite of adverse neonatal outcomes
Number of subjects: 0
Study: 27871723

Group type: EXPERIMENTAL
Intervention: Bevacizumab added to chemotherapy
Number of subjects: 133

Group type: COMPARATOR
Intervention: Single-agent chemotherapy alone
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 133
Study: 25966138

Group type: EXPERIMENTAL
Intervention: Disposcope endoscope (Group D)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Macintosh laryngoscope (Group M)
Number of subjects: 40
Study: 23741997

Group type: EXPERIMENTAL
Intervention: SRP+Er:YAG laser
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: SRP+topical gaseous ozone
Number of subjects: 30

Group type: COMPARATOR
Intervention: SRP alone
Number of subjects: 30
Study: 21273939

Group type: EXPERIMENTAL
Intervention: HPV‐16/18 vaccine administered according to the alternative schedule (0‐1‐12 months)
Number of subjects: 804

Group type: COMPARATOR
Intervention: HPV‐16/18 vaccine administered according to the standard schedule (0‐1‐6 months)
Number of subjects: 804
Study: 18971567

Group type: EXPERIMENTAL
Intervention: ICD implantation with limited induction of ventricular fibrillation (VF)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: ICD implantation with limited induction of VF
Number of subjects: 16
Study: 17633249

Group type: EXPERIMENTAL
Intervention: Nasal operation (septoplasty, radiofrequency reduction of inferior turbinate, adenoidectomy, functional endoscopic operation)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: UPPP (Uvulopalatopharyngoplasty)
Number of subjects: 88

Group type: COMPARATOR
Intervention: UPPP
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Nasal operation (second phase for group B)
Number of subjects: 88
Study: 15205983

Group type: EXPERIMENTAL
Intervention: Video colposcopy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Regular colposcopy
Number of subjects: 60
Study: 11913307

Group type: EXPERIMENTAL
Intervention: Baking soda-containing chewing gum (AHDC)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Experimental gum formulations
Number of subjects: 126
Study: 9286747

Group type: EXPERIMENTAL
Intervention: Calcium supplements (mean calcium dose: 1050 mg)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Dietary calcium
Number of subjects: 14
Study: 7950469

Group type: EXPERIMENTAL
Intervention: Educational sessions for physicians to standardize knowledge of the recommendations of the Canadian Hypertension Society on hypertension treatment and specific operational incentives to improve hypertension control.
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control Group A (100 patients before and after)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control Group B (60 patients before and after)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Patients listed in the recall card file
Number of subjects: 200
Study: 2438648

Group type: EXPERIMENTAL
Intervention: 4 ABVD chemotherapy
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 20 Gy radiotherapy
Number of subjects: 120

Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 120
Study: 30549271

Group type: EXPERIMENTAL
Intervention: Piezosurgery (PS)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Conventional drill
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Piezosurgery (PS) and Conventional drill
Number of subjects: 14
Study: 28718232

Group type: EXPERIMENTAL
Intervention: Intravenous steroids (120 mg of injection Depomedrol) administered 1 hour before surgery
Number of subjects: 65

Group type: COMPARATOR
Intervention: Conventional MRM without steroids (Group A)
Number of subjects: 65
Study: 25454942

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 23843375

Group type: EXPERIMENTAL
Intervention: Osteopathic manipulative treatment (OMT) protocol consisting of myofascial release to the thoracic inlet, the splenic pump, and the pedal lymphatic pump for 6 minutes.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Light touch protocol applied to the same body areas for 6 minutes.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Osteopathic manipulative treatment (OMT) protocol
Number of subjects: 20
Study: 21926038

Group type: EXPERIMENTAL
Intervention: Cryosurgery during daily imiquimod application (Arm I)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Adjuvant imiquimod (Arm II)
Number of subjects: 16
Study: 19183841

Group type: EXPERIMENTAL
Intervention: Nateglinide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Repaglinide
Number of subjects: 0
Study: 16924022

Group type: EXPERIMENTAL
Intervention: Oxcarbazepine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Carbamazepine/Valproate
Number of subjects: 0
Study: 15492493

Group type: EXPERIMENTAL
Intervention: Present group (current patients)
Number of subjects: 175

Group type: COMPARATOR
Intervention: Past group (patients from 15 years ago)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Children aged 6 or younger in the present group
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Children aged 7 or older in both groups
Number of subjects: 175
Study: 11533366

Group type: EXPERIMENTAL
Intervention: Montelukast 4 mg chewable tablet
Number of subjects: 689

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 689
Study: 9506726

Group type: EXPERIMENTAL
Intervention: Levothyroxine (L‐T4) suppressive therapy
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 83
Study: 8172437

Group type: EXPERIMENTAL
Intervention: Fluconazole, 150 mg, once daily
Number of subjects: 820

Group type: COMPARATOR
Intervention: Oral amphotericin B, 500 mg every 6 hours
Number of subjects: 820
Study: 3168767

Group type: EXPERIMENTAL
Intervention: Beer drinking group
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study: 31880956

Group type: EXPERIMENTAL
Intervention: Randomised study design
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Experimental design
Number of subjects: 0
Study: 31072385

Group type: EXPERIMENTAL
Intervention: Compliant regular users (C-RU) of advanced PAP therapy
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Subthreshold users (SC-RU) of advanced PAP therapy
Number of subjects: 96

Group type: COMPARATOR
Intervention: Noncompliant users (NC-MU) of advanced PAP therapy
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Hours of weekly PAP use
Number of subjects: 96
Study: 30066463

Group type: EXPERIMENTAL
Intervention: 6-month support programme consisting of psychoeducation, social support, and behavioural cognitive therapy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided)
Number of subjects: 30
Study: 25714035

Group type: EXPERIMENTAL
Intervention: Green tea consumption
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Black tea consumption
Number of subjects: 8
Study: 25141110

Group type: EXPERIMENTAL
Intervention: 1.0 W/cm2 continuous ultrasound treatment
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: 1.0 W/cm2 1:4 pulsed ultrasound treatment
Number of subjects: 46

Group type: COMPARATOR
Intervention: 0 W/cm2 ultrasound treatment (placebo)
Number of subjects: 46
Study: 21707451

Group type: EXPERIMENTAL
Intervention: Fish oil (FO) supplementation, 2 g/day for 15 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Primrose oil (PO) supplementation (control)
Number of subjects: 0
Study: 18973889

Group type: EXPERIMENTAL
Intervention: Low-dose oral contraceptive containing ethinyl estradiol and drospirenone for three cycles
Number of subjects: 20
Study: 17207126

Group type: EXPERIMENTAL
Intervention: Assertive Continuing Care (ACC)
Number of subjects: 183

Group type: COMPARATOR
Intervention: Usual Continuing Care (UCC)
Number of subjects: 183
Study: 16395988

Group type: EXPERIMENTAL
Intervention: Insulin glargine in combination with oral antidiabetic drugs (OADs)
Number of subjects: 678

Group type: COMPARATOR
Intervention: Conventional insulin therapy
Number of subjects: 678

Group type: EXPERIMENTAL
Intervention: Insulin glargine plus OADs
Number of subjects: 678
Study: 12475159

Group type: EXPERIMENTAL
Intervention: Welded titanium frameworks
Number of subjects: 58

Group type: COMPARATOR
Intervention: Conventional cast-gold alloy frameworks
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 58
Study: 9893589

Group type: EXPERIMENTAL
Intervention: ICSC
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: POAG
Number of subjects: 34

Group type: COMPARATOR
Intervention: Normal subjects
Number of subjects: 34
Study: 8594942

Group type: EXPERIMENTAL
Intervention: Atrial natriuretic peptide (ANP) infusion (2 pmol.kg‐1.min‐1 for 2 h)
Number of subjects: 8
Study: 2242369

Group type: EXPERIMENTAL
Intervention: 8 mg of salbutamol orally 30 min before vaginal administration of 2 mg prostaglandin E2 gel
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo orally 30 min before vaginal administration of 2 mg prostaglandin E2 gel
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 8 mg of salbutamol
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 643495

Group type: EXPERIMENTAL
Intervention: Preferred serial practice
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Non-preferred serial practice
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Preferred sequence practice
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Non-preferred sequence practice
Number of subjects: 44

Group type: COMPARATOR
Intervention: Order of practice
Number of subjects: 44
Study: 27128107

Group type: EXPERIMENTAL
Intervention: BD Simplist (BDS)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Carpuject (CJ)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Traditional vial-and-syringe process (TVSP)
Number of subjects: 24
Study: 29034598

Group type: EXPERIMENTAL
Intervention: Two-window technique without membrane coverage (Test Group)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Solo-window technique with membrane coverage (Control Group)
Number of subjects: 20
Study: 25041807

Group type: EXPERIMENTAL
Intervention: Turbinate-septal suture plus nasal packing (group B)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Nasal (group A)
Number of subjects: 120
Study: 23588193

Group type: EXPERIMENTAL
Intervention: Endurance training (AT)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Strength training (ST)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (CON(CH))
Number of subjects: 39
Study: 20584759

Group type: EXPERIMENTAL
Intervention: Stability shoe
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Motion control shoe
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Neutral shoe
Number of subjects: 81

Group type: COMPARATOR
Intervention: Highly pronated foot
Number of subjects: 81
Study: 19953773

Group type: EXPERIMENTAL
Intervention: Bonded with a two-step, total-etch adhesive (Single Bond 2)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Lined with a resin-modified GIC liner (Fuji Lining LC), then bonded with total-etch adhesive
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Bonded with a two-step, self-etch adhesive (Clearfil SE Bond)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Lined with the GIC liner, then bonded with self-etch adhesive
Number of subjects: 70
Study: 16761834

Group type: EXPERIMENTAL
Intervention: Shannon entropy (ShEn)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Approximate entropy (ApEn)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lempel‐Ziv complexity (LZC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higuchi fractal dimension (HFD)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Spectral entropy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ramsay score (clinical depth of sedation score)
Number of subjects: 0
Study: 15277410

Group type: EXPERIMENTAL
Intervention: Subcutaneous insulin aspart every hour (SC-1h)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Subcutaneous insulin aspart every 2 hours (SC-2h)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Intravenous regular insulin (IV)
Number of subjects: 45
Study: 11441410

Group type: EXPERIMENTAL
Intervention: Docetaxel plus gemcitabine
Number of subjects: 317

Group type: COMPARATOR
Intervention: Docetaxel plus cisplatin
Number of subjects: 317

Group type: EXPERIMENTAL
Intervention: Docetaxel plus vinorelbine
Number of subjects: 317

Group type: EXPERIMENTAL
Intervention: Docetaxel plus irinotecan
Number of subjects: 317
Study: 9205509

Group type: EXPERIMENTAL
Intervention: 250 mg terbinafine daily for 6 weeks
Number of subjects: 148

Group type: COMPARATOR
Intervention: 250 mg terbinafine daily for 12 weeks
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: 250 mg terbinafine daily for 6 weeks (in patients with fingernail infection)
Number of subjects: 148
Study: 7961582

Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 83

Group type: COMPARATOR
Intervention: Typical neuroleptics
Number of subjects: 83
Study: 3944997

Group type: EXPERIMENTAL
Intervention: Disposable pressure transducers changed every two days
Number of subjects: 157

Group type: COMPARATOR
Intervention: Disposable pressure transducers changed every four days
Number of subjects: 157

Group type: COMPARATOR
Intervention: Disposable pressure transducers changed every eight days
Number of subjects: 157
Study: 29380961

Group type: EXPERIMENTAL
Intervention: Patient-initiated self-monitoring service
Number of subjects: 12

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 12
Study: 26893403

Group type: EXPERIMENTAL
Intervention: Illustrated instruction on how to collect a clean uncontaminated midstream urine sample
Number of subjects: 240

Group type: COMPARATOR
Intervention: No illustrated instruction (control group)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Illustrated instruction
Number of subjects: 240
Study: 25037054

Group type: EXPERIMENTAL
Intervention: Comprehensive distancing (CD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cognitive challenge task
Number of subjects: 0
Study: 22854553

Group type: EXPERIMENTAL
Intervention: A-solution (oral gargling with blended essential oils diluted with distilled water)
Number of subjects: 66
Study: 15951645

Group type: EXPERIMENTAL
Intervention: Visual Analog Scale
Number of subjects: 168

Group type: COMPARATOR
Intervention: 4-point verbal rating scale
Number of subjects: 168
Study: 12029406

Group type: EXPERIMENTAL
Intervention: PEP mask plus assisted coughing (Group A)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Assisted coughing alone (Group B)
Number of subjects: 27
Study: 10634176

Group type: EXPERIMENTAL
Intervention: CD34+ selected blood progenitor cells
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonselected blood progenitor cells
Number of subjects: 0
Study: 7554018

Group type: EXPERIMENTAL
Intervention: Children identified as night blind (mean serum vitamin A level 16.3 micrograms/dl; 95% CI, 13.9‐18.7)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Children identified as not night blind (mean serum vitamin A level 23.6 micrograms/dl; 95% CI, 21.3‐25.9)
Number of subjects: 105
Study: 2309102

Group type: EXPERIMENTAL
Intervention: Dynamic training
Number of subjects: 67

Group type: COMPARATOR
Intervention: Static training
Number of subjects: 67
Study: 7250591

Group type: EXPERIMENTAL
Intervention: Digoxin (0.375 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Beta-methyldigoxin (0.25 mg/day)
Number of subjects: 0
Study: 29940089

Group type: EXPERIMENTAL
Intervention: edoxaban
Number of subjects: 1293

Group type: COMPARATOR
Intervention: warfarin
Number of subjects: 1293
Study: 27980008

Group type: EXPERIMENTAL
Intervention: Arhalofenate 800 mg + Febuxostat 80 mg
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Arhalofenate 600 mg + Febuxostat 80 mg
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Arhalofenate 800 mg + Febuxostat 40 mg
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Arhalofenate
Number of subjects: 32

Group type: COMPARATOR
Intervention: Febuxostat
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Combination of Arhalofenate and Febuxostat
Number of subjects: 32
Study: 26184655

Group type: EXPERIMENTAL
Intervention: Peer-led BLS training
Number of subjects: 1087

Group type: COMPARATOR
Intervention: Professional-led BLS training
Number of subjects: 1087
Study: 24438566

Group type: EXPERIMENTAL
Intervention: Accelerated osteogenic orthodontic group (AOO)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 10
Study: 20963840

Group type: EXPERIMENTAL
Intervention: Azithromycin 10 mg/kg/day for 7 days followed by 5 mg/kg/day for a maximum of 6 weeks
Number of subjects: 220

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Azithromycin in Ureaplasma subgroup
Number of subjects: 220

Group type: COMPARATOR
Intervention: Placebo in Ureaplasma subgroup
Number of subjects: 220
Study: 18320254

Group type: EXPERIMENTAL
Intervention: Genetically modified potatoes (3 mg zeaxanthin)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Wild-type control potatoes (0.14 mg zeaxanthin)
Number of subjects: 3
Study: 16233990

Group type: EXPERIMENTAL
Intervention: Lacto-ovo-vegetarian diet (32 treatment sessions over 12 months)
Number of subjects: 197

Group type: COMPARATOR
Intervention: Standard diet (discarded 15 subjects who preferred this diet)
Number of subjects: 197
Study: 12760986

Group type: EXPERIMENTAL
Intervention: Celecoxib 400 mg
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg
Number of subjects: 93

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study: 10712997

Group type: EXPERIMENTAL
Intervention: Specific inspiratory muscle training (SIMT) for 3 months
Number of subjects: 23

Group type: COMPARATOR
Intervention: Sham training (Control)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Specific inspiratory muscle training (SIMT)
Number of subjects: 23
Study: 9198292

Group type: EXPERIMENTAL
Intervention: nizatidine (2 x 150 mg twice daily), amoxicillin (2 x 250 mg four times daily), clarithromycin (2 x 250 mg three times daily) for two weeks (niz-amox-clar group, N = 25)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: omeprazole (20 mg twice daily), clarithromycin (2 x 250 mg three times daily) for two weeks (ome-clar group, N = 25)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: bismuth subsalicylate (300 mg four times daily), amoxicillin (2 x 250 mg four times daily), metronidazole (250 mg four times daily) for two weeks (triple therapy group, N = 25)
Number of subjects: 75
Study: 1545557

Group type: EXPERIMENTAL
Intervention: Percutaneous removal
Number of subjects: 50

Group type: COMPARATOR
Intervention: Surgical removal
Number of subjects: 50
Study: 4085468

Group type: EXPERIMENTAL
Intervention: Digby‐Leigh valve with inspiratory resistance of 7 cmH2O l‐1s and high expiratory resistance of 25 cmH2O l‐1s (DLS)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Inspiratory resistive load of 12 cmH2O l‐1s (IRS1)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Inspiratory resistive load of 25 cmH2O l‐1s (IRS2)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Low-resistance control system
Number of subjects: 15
Study: 29997249

Group type: EXPERIMENTAL
Intervention: Low-dose mTOR inhibitor therapy (combination of BEZ235 and RAD001)
Number of subjects: 264